5th Immunotherapy Of Cancer Conference

The Leading International Cancer Immunotherapy Conference in Europe

March 19-21, 2018

Berlin, Germany

www.itoc-conference.eu

Save the Date
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME LETTER</td>
<td>4</td>
</tr>
<tr>
<td>CANCER DRUG DEVELOPMENT FORUM &amp; PARTNERS</td>
<td>5</td>
</tr>
<tr>
<td>ORGANISING PARTNERS</td>
<td>5</td>
</tr>
<tr>
<td>CONFERENCE COMMITTEE</td>
<td>6</td>
</tr>
<tr>
<td>ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)</td>
<td>6</td>
</tr>
<tr>
<td>PROGRAMME AT A GLANCE</td>
<td>7</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td>8</td>
</tr>
<tr>
<td>POSTERS</td>
<td>10</td>
</tr>
<tr>
<td>FLOORPLAN</td>
<td>13</td>
</tr>
<tr>
<td>ACKNOWLEDGMENTS</td>
<td>14</td>
</tr>
<tr>
<td>EXHIBITORS</td>
<td>15</td>
</tr>
<tr>
<td>PARTNERS</td>
<td>16</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>17</td>
</tr>
<tr>
<td>CORPORATE SATELLITE SYMPOSIUM</td>
<td>21</td>
</tr>
</tbody>
</table>
WELCOME LETTER

Welcome to the fourth edition of the Immunotherapy of Cancer conference (ITOC4), the premier meeting for education, scientific exchange and networking within cancer immunotherapy.

This meeting has been growing rapidly into a global platform for translational research in the field of immuno-oncology.

The scientific programme with an international faculty will focus on many topics such as Preclinical models, Micro-environment and Immune Regulation, Emerging concepts and novel targets, Combination therapy, Monitoring of immune response in the clinic, Therapeutic antibodies and Cell therapy.

Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development and in cooperation with Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC-4 in the beautiful city of Prague.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the evaluation form at the end of the conference and please do not hesitate to reach out to our team on site or via email (itoc@medacad.org).

Yours sincerely,

Prof. Christoph Zielinski
Conference President

Prof. Howard Kaufman
Conference President

Prof. Volkmar Nüssler
Munich Tumour Center

Prof. Heinz Zwierzina
Scientific Chairman
CANCER DRUG DEVELOPMENT FORUM

The Cancer Drug Development Forum (CDDF) is a not-for-profit organisation registered in Austria. It was established in 2001 as Biotherapy Development Association (BDA) and changed name in 2014 to Cancer Drug Development Forum (CDDF).

While BDA’s focus was initially around immunotherapy, in recent years the association has embraced all forms of cancer drug development and therefore wanted a name that better reflects the organisation’s breadth of interests and activities.

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past 14 years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF’s list of publications at: www.cddf.org

ORGANISING PARTNERS

ITOC4 POSTER PRIZE

We are proud to announce the ITOC 4 Poster Prize which will be awarded at the 4th Immunotherapy of Cancer Conference thanks to the generous support of the Tumor Center Munich.

Prizes will be awarded to the three best poster presentations. The winners will receive a certificate and a prize of EUR 1000,-/700,-/500,-.

Winners are selected by the scientific committee according to the following criteria:

- Scientific content/methodology
- Novelty and originality of research
- Ability of the author to present the poster in a concise and clear manner and to answer questions during the dedicated poster sessions.

Posterreviewing-Committee:

- Chairman: Prof. Dr. Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Prof. Dr. Bernhard Fox (Providence Cancer Center, USA)
- Prof. Dr. Lubos Petruzelka (Charles University, Czech Republic)
- Prof. Dr. Eric Tartour (Hôpital Européen Georges-Pompidou, France)
CONFERENCE COMMITTEE

CONFERENCE PRESIDENTS
- Christoph Zielinski (Medical University of Vienna, Austria)
- Howard L. Kaufman (Rutgers Cancer Institute of New Jersey, USA)

CHAIRMAN OF THE SCIENTIFIC COMMITTEE
- Heinz Zwierzina (Innsbruck University, Austria)

SCIENTIFIC COMMITTEE
- Paolo A. Ascierto (Istituto Nazionale Tumori, Italy)
- Lisa H. Butterfield (University of Pittsburgh, USA)
- Bernard A. Fox (Providence Cancer Center, USA)
- Leif G. Hakansson (Universitetssjukhuset Linköping, Sweden)
- Robert F. Hawkins (The Christie Hospital, United Kingdom)
- Samir N. Khleif (Georgia Regents University, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, USA)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Lubos Petruzelka (Charles University, Czech Republic)
- Jose Saro (Roche, Switzerland)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Chinese American Hematology and Oncology Network, USA)
- Zhen Su (Merck KGaA, Germany)
- Mario Sznol (Yale School of Medicine, USA)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Rostislav Vyzula (Masaryk Memorial Cancer Institute, Czech Republic)

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

The 4th ImmunoTherapy of Cancer Conference, Prague, Czech Republic (March 20 – 22, 2017) has been granted 12 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants who attend the above mentioned activity to validate their credits in their own country.
### PROGRAMME AT A GLANCE

#### Monday, March 20, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>10:30</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>11:00</td>
<td>Opening Plenary Symposium Preclinical models</td>
</tr>
<tr>
<td>12:50</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:30</td>
<td>Plenary Symposium Micro-environment and Immune Regulation</td>
</tr>
<tr>
<td>17:40</td>
<td>Poster Viewing with Presenters (Topic 2)</td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

#### Tuesday, March 21, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Plenary Symposium Emerging concepts and novel targets</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Symposium Combination therapy</td>
</tr>
<tr>
<td>12:50</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00</td>
<td>Lifetime Achievement Award</td>
</tr>
<tr>
<td>14:45</td>
<td>Plenary Symposium Monitoring of immune response in the clinic</td>
</tr>
<tr>
<td>15:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:15</td>
<td>Plenary Symposium Monitoring of immune response in the clinic (cont.)</td>
</tr>
<tr>
<td>17:30</td>
<td>Poster Viewing with Presenters (Topics 1,3,4,5,6)</td>
</tr>
<tr>
<td>19:30</td>
<td>ITOC4 Conference Dinner</td>
</tr>
</tbody>
</table>

#### Wednesday, March 22, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Plenary Symposium: Treatment of Immune Excluded and Immune Desert Tumor</td>
</tr>
<tr>
<td>09:30</td>
<td>Plenary Symposium Therapeutic antibodies</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Plenary Symposium Cell therapy</td>
</tr>
<tr>
<td>12:15</td>
<td>Best Poster Awards &amp; Closing Remarks</td>
</tr>
<tr>
<td>12:45</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
**MONDAY, MARCH 20, 2017**

**10.30 – 11.00**
**Welcome Address**  
Christoph Zielinski, Vienna, Austria

**11.00 – 12.50**
**Opening Plenary Symposium - Preclinical models and translational research**  
Chair: Howard Kaufman, New Brunswick, NJ, USA - Heinz Zwierzina, Innsbruck, Austria

**11.00 – 11.10**
**Welcome Address**

**11:10 - 11:40**
**The need for preclinical models for immunotherapy**  
Mario Sznol, New Haven, CT, USA

**11:40 - 12:00**
**Preclinical and early clinical development of an autophagosome vaccine using immunomonitoring and genomics data**  
David Page, Portland, OR, USA

**12:00 - 12:20**
**Multispectral imaging of the tumour environment**  
Bernard A. Fox, Portland, OR, USA

**12:20 - 12:35**
**Tumor regression induced by type I interferon triggering in mammary tumor-bearing mice**  
Nadege Bercovici, Paris, France (A9)

**12:35 - 12:50**
**Small-molecule inhibitors of ecto-nucleotidase CD73 result in strong activation of human and mouse CD8+ T cells in the presence of exogenous AMP, affect tumor growth and positively affect anti-tumor immunity in mouse syngeneic tumor models**  
Annette Becker, Hayward, CA, USA (A21)

**12:50 – 14.00**
**Lunch**

**14.00 – 15.00**
**Satellite Symposium – For further information please see page 21**

**15.00 – 15.30**
**Coffee Break**

**15.30 - 17:40**
**Plenary Symposium - Micro-environment and Immune Regulation**  
Chair: Bernard A. Fox, Portland, OR, USA - Leif Hakansson, Linköping, Sweden

**15:30 - 15:50**
**Targeting immunosuppressive enzymes in the tumor microenvironment**  
Benoit van den Eynde, Brussels, Belgium

**15:50 - 16:10**
**Overcoming metabolic barriers to antitumor immunity**  
Greg M. Delgoffe, Pittsburgh, PA, USA

**16:10 - 16:30**
**Mechanisms of exhaustion in T-Cells and tumor microenvironment**  
Ignacio Melero, Navarra, Spain

**16:30 - 16:50**
**Control of regulatory T cell function**  
Zhai Li, Charleston, SC, USA

**16:50 - 17:10**
**NK cells in the tumor microenvironment - implications for therapy**  
Lorenzo Moretta, Rome, Italy

**17:10 - 17:25**
**Monocytic myeloid derived suppressor cells (mMDSC) determine outcome in ovarian cancer**  
Thais Baert, Leuven, Belgium (A17)

**17:25 - 17:40**
**A predictive PD-L1*CD8 cell density score for NSCLC patients treated with Durvalumab**  
Andreas Spitzmüller, Munich, Germany (A3)

**17.40**
**Posterviewing with Presenters (Topic 2)**

**18.30**
**Welcome Reception**

**TUESDAY, MARCH 21, 2017**

**08:30 - 10:00**
**Plenary Symposium - Emerging concepts and novel targets**  
Chair: Samir Khleif, Augusta, GA, USA - Wenru Song, Arlington, MA, USA

**08:30 - 09:00**
**Novel targets and approaches for immunotherapy development**  
Aurélien Marabelle, Paris, France

**09:00 - 09:20**
**Targeting CCR5 for macrophage repolarization for cancer immunotherapy**  
Niels Holama, Heidelberg, Germany

**09:20 - 09:40**
**Vaccination during myeloid cell depletion**  
Marij Welters, Leiden, Netherlands

**09:40 - 10:00**
**Therapeutic targeting of B cells**  
Michael von Bergwelt-Baildon, Cologne, Germany

**10:00 - 10:15**
**A tumor mitochondria vaccine protect against experimental renal cell carcinoma**  
Andrea Facciabene, Philadelphia, PA, USA (B1)
10:15 - 10:30
In vivo targeting of TGF-beta inhibitors to CD8+ T cells via ultra-small amphiphilic Nanoparticles
Sabrina Yu-Sang Yang, Cambridge, MA, USA (A36)

10:30 – 11:00
Coffee Break

11:00 - 12:50
Plenary Symposium - Combination therapy
Chair: Zhai Li, Charleston, SC, USA - Paolo Ascierto, Naples, Italy

11:00 – 11:20
Combination of Check Point Blockade for Cancer Therapy
Patrick A. Ott, Boston, MA, USA

11:20 - 11:40
Combining vaccination with inhibition of T cell signaling
Samir Khleif, Augusta, GA, USA

11:40 - 12:00
Dendritic cell therapy in combination with checkpoint inhibition
Bart Neyns, Brussels, Belgium

12:00 - 12:20
Immunogenic chemotherapy
Angus Dalgleish, London, United Kingdom

12:20 - 12:35
89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: role of IL-2 receptor-binding and CEA-mediated tumor accumulation in a dose-dependent manner
C. Willemien Menke-van der Houven van Oordt, Amsterdam, Netherlands (B2)

12:35 - 12:50
Doxorubicin loaded immunoliposomes coupled to anti-MAGE A1 TCR-like scFv for improved drug delivery to melanoma
Mesha Saeed, Rotterdam, Netherlands (A40)

12.50 – 14.00
Lunch

14.00 – 14.45
Lifetime Achievement Award
Cancer immunotherapy: the narrow road between inefficacy and toxicity
Thierry Boon, Brussels, Belgium

14:45 - 17:25
JOINT ESMO- ITOC Session
Plenary Symposium - Monitoring of immune response in the clinic (cont.)
Chair: Eric Tartour, Paris, France - Christoph Zielinski, Vienna, Austria

14:45 - 15:05
Epigenetic immunomodulation for cancer immunotherapy
Michele Maio, Siena, Italy

15:05 - 15:25
Are immune-mediated adverse events really autoimmunity?
Paolo Ascierto, Naples, Italy

15:25 - 15:45
Prognostic and predictive value of multiplex in situ immunofluorescence in oncology
Eric Tartour, Paris, France

15:45 – 16:15
Coffee Break

16:15 - 16:35
Identification of biomarkers using combined proteomic and genomic approaches
Graham Ball, Nottingham, United Kingdom

16:35 - 16:50
An Immunoinformatics Framework for Identification of Personalized Tumor Epitopes in Cancer
Tanushree Jaitly, Erlangen, Germany (A46)

16:50 - 17:10
Proteomic test identifies sensitivity and resistance to immunotherapy in cancer Patients
Jeffrey Weber, New York, NY, USA (A31)

17:10 – 17:25
Baseline peripheral blood biomarkers predict clinical outcome of advanced melanoma patients treated with ipilimumab: single institution real-life data experience
Lenka Zdrazilova-Dubska, Brno, Czech Republic (A34)

19.30
ITOC4 Conference Dinner

WEDNESDAY, MARCH 22, 2017

08.30 – 09.30
Treatment of Immune Excluded and Immune Desert Tumors
Chair: Paolo Ascierto

08:30 - 08:50
The role of Batf-3 DC in the non-T cell-inflamed tumor microenvironment
Stefani Spranger, Cambridge, MA USA

08:50 - 09:10
Challenges and Opportunities for Reprogramming the Tumor Microenvironment
Lei Zheng, Baltimore, MD, USA

09:10 - 09:30
Combinatorial Immunotherapy and Anti-Angiogenic Approaches
Lana Kandalaft, Lausanne, Switzerland

09:30 - 10:30
Plenary Symposium - Therapeutic antibodies
Chair: Sebastian Kobold, Munich, Germany - Barbara Seliger, Halle, Germany
**09:30 - 09:50**  
Tumour targeting antibodies: from tumor killing to immunity triggering  
Yang Xin Fu, Dallas, TX, USA

**09:50 - 10:10**  
Translating inhibitory Fc receptor biology into novel therapeutic approaches  
Frank Nimmerjahn, Erlangen, Germany

**10:10 - 10:25**  
Anti-proliferative & pro-apoptotic effects induced by simultaneous inactivation of HER1 & HER2 through endogenous polyclonal antibodies  
Narjara González Suárez, Havana, Cuba (A43)

**10:30 – 11.00**  
Coffee Break

**11:00 - 12:10**  
Plenary Symposium - Cell therapy  
Chair: Robert Hawkins, Manchester, United Kingdom – Stefan Endres, Munich, Germany

**11:00 – 11:30**  
T-cell therapy - what have we learned about the role of Pre-conditioning chemotherapy and cytokines support?  
Robert Hawkins, Manchester, United Kingdom

**11:30 - 11:50**  
Editing of neoepitopes during T cell therapy  
Els Verdegaal, Leiden, Netherlands

**11:50 - 12:10**  
A novel platform for MHC-unrestricted adoptive T cell therapy  
Sebastian Kobold, Munich, Germany

**12:15**  
Best Poster Awards & Closing Remarks

**12.45 – 13.30**  
Lunch

---

**POSTER PRESENTATIONS**

### 1. PRECLINICAL MODELS

**A1**  
Intratumoral immunotherapy. B16-F10 murine melanoma model  
Jan Ženka, České Budějovice, Czech Republic

**B3**  
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo  
Tomokazu Aoki, Kyoto, Japan

**A2**  
Assessing humanized mouse models for cancer immunotherapy  
Laure Loumagne, Vitry, France

**A4**  
The influence of specific cytokines on cancer microtissue infiltrating cytotoxic T lymphocyte subpopulations  
Stefan Koeck, Innsbruck, Austria

### 2. TUMOR IMMUNITY AND MICROENVIRONMENT

**B4**  
Immunomonitoring of the patients with colorectal cancer  
Jan Spacek, Prague, Czech Republic

**A10**  
A new method to generate mature (leukemia-derived) dendritic cells that improve antileukemic T-cell reactivity from mononuclear cells or whole blood from healthy volunteers or patients with AML  
Daniel Amberger, Munich, Germany

**A11**  
Interleukin-22 (IL-22) does not influence methycholanthren-A-mediated tumorigenesis  
Anamarija Markota, Munich, Germany

**A12**  
Inhibition of CD39 and CD73 by 3rd generation antisense oligonucleotides to improve immunity against tumors  
Tamara Hilmenyuk, Planegg/Martinsried, Germany

**A13**  
The immunome in early stage NSCLC: flow cytometry analyses of immunological subpopulations in tumor, lung tissue and whole blood  
Gabriele Gamerith, Innsbruck, Austria

**A14**  
Mitochondrial mass analysis in CD8+ T cells from lung cancer patients  
Heriberto Prado-Garcia, Mexico City, Mexico

**A15**  
Targeting hIDO1 with 3rd generation antisense oligonucleotides for modulation of the tumor microenvironment  
Richard Klar, Martinsried, Germany

**A16**  
Relevance of systemic immunosuppression in ovarian cancer patients  
An Coosemans, Leuven, Belgium

**B5**  
Profiling Compounds in Human Primary Cell BioMAP® Systems for Drug Discovery and Development in Cancer Immunotherapy  
Alexander Baumann, Birmingham, United Kingdom
A18  GBP1 expression in colorectal cancer liver metastasis associates with increased CD8+ lymphocyte invasion and confers better prognosis
    Johannes Laengle, Vienna, Austria

B6  CCR4 activated by TNF-α facilitate metastasis via ERK/NF-κB pathway in colon cancer
    Xiaohui Shen, Shanghai, China

A19  Circulating myeloid-derived suppressor cells (MDSC) are increased in breast and colorectal cancer patients
    Lenka Zdrazilova-Dubska, Brno, Czech Republic

A20  Gene expression profile of the tumor microenvironment from 40 NSCLC FFPE and matched fresh frozen samples using a targeted NGS solution
    Chris Allen, South San Francisco, United States

B7  Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
    Boern Wendik, Rodgau, Germany

A22  Aberrant status of glutathione metabolism predict prognosis of colorectal cancer patients
    Shuai Yin, Muenchen, Germany

A23  Gastric cancer with lymphoid stroma: A study of clinico-pathological profile, Epstein-Barr virus, microsatellite instability, tumour immune microenvironment and PD-L1 status
    Irene Gullo, Porto, Portugal

A24  Ansercept (APG101) a CD95L-neutralizing compound protects immune cells from activation-induced cell death without compromising their anti-tumour activity
    Christian Merz, Heidelberg, Germany

A25  Recognition of tumor-associated self-protein Her2 by T cells of breast cancer patients and healthy donors
    Mariana Pinha, São Paulo, Brazil

A26  Effects of neoadjuvant chemotherapy on immune cell subsets in patients with breast cancer: A transcriptomic and phenotypic analysis
    Stephanie Mc Ardle, Nottingham, United Kingdom

A27  Digital Pathology - a Key to Discover new Biomarkers?
    Carol Immanuel Geppert, Erlangen, Germany

A28  Glucocorticoid receptor agonist-mediated induction of miRNA-708 modulates breast cancer proliferation and metastasis via NF-κB signaling pathway
    KJ Senthil Kumar, Taichung, Taiwan

A29  Hexavalent CD27 agonist HERA-CD27L enhances anti-tumour response of effector T-cells in syngeneic mouse models of colorectal cancer
    Christian Merz, Heidelberg, Germany

B2  Immune-related effects of the fat in ovarian cancer
    Meggy Suarez-Carmona, Heidelberg, Germany

3. THERAPEUTIC MODULATION AND MONITORING OF IMMUNE RESPONSE

A30  MuScreenTM : a panel of well-characterized syngeneic models for in vivo screening in a high-efficient manner
    Lan Zhang, Taicang, China

A32  Number, composition and/or antileukemic activity of (DC-stimulated) invariant NKT-, NK- and CIK-cells is predictive for outcome of patients with AML, ALL and CLL
    Corinna Boeck, Munich, Germany

A33  Clinical Experience of Nivolumab as a Second Line Treatment of Non-Small Cell Lung Cancer
    Young-Chul Kim, Jeonnam, Republic of Korea

B8  Therapeutic effect of immune response due to cryoablation
    Shinji Osada, Gifu, Japan

A35  HMGBl plasma concentrations are associated with overall survival in lung adenocarcinoma patients
    D Aguilar-Cazares, Mexico City, Mexico

LB4  Pretreatment Immune Status is a prediction marker of progression-free survival in chemotherapy treated metastatic colorectal cancer patients
    Yuji Heike, Tokyo, Japan

4. COMBINATION THERAPY

B9  The significance of histopathological evaluation of pancreatic fibrosis to estimate pancreas cancer progression
    Shinji Osada, Gifu, Japan

A37  The dSLIM family of TLR9 agonists - benefit of the combination with checkpoint inhibitors in tumor models
    Barbara Volz, Berlin, Germany

A38  Study of immunogenic cell death markers in lung adenocarcinoma cell lines treated with therapeutic agents
    Rodolfo Chavez-Dominguez, Mexico City, Mexico

A39  Complete response of stage IIIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
    Ralf Kleef, Vienna, Austria

A41  Synergistic effects of P2X7 and doxorubicin in tumor cells
    Sana Javed, Hamburg, Germany

A42  Cancer immunotherapy with sequential administration of trabectedin and nivolumab in advanced soft tissue sarcoma
    Erlinda Gordon, Santa Monica, United States

B10  Radiation recall pneumonitis induced by double immune checkpoint blockade
    Petr Hausner, Baltimore, United States
5. Anti-Cancer Vaccines

A44 Development of a novel immunotherapy with Toll-like and Nod-like receptors synergy for targeted cancer therapy

Célia Jacoberger-Foissac, Illkirch, France

A45 Phase I clinical study for validation of photochemical internalisation (fimaVacc) - a novel technology for enhancing cellular immune responses important for therapeutic effect of peptide- and protein based vaccines

Tone Otterhaug, Oslo, Norway

6. Adoptive Cell Therapy

A47 Preclinical characterization of a PD-1-CD28 fusion receptor for T cell-based immunotherapy of Non-Hodgkin Lymphoma

Felicitas Rataj, Munich, Germany

B11 Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells

Felicitas Rataj, Munich, Germany

A48 Dominant negative tumor growth factor beta receptor 2 enables T cell activity in a murine pancreatic tumor model

Bruno Loureiro Cadilha, München, Germany

LB5 Detection of highly prevalent and functional LAA-specific cytotoxic T lymphocytes in healthy individuals implicates new strategies for adoptive T cell therapy of relapsed leukemia

Sarah Matko, Dresden, Germany
**4TH IMMUNOTHERAPY OF CANCER CONFERENCE**

**FLOORPLAN - LEVEL 2 - PCC**

- **Main Lecture Hall**
- **Exhibition & Catering (Forum Hall Foyer 2)**
- **Registration Desk**
- **ITOC4 Room**
- **Preview Room**
- **Outside Terrace**

**Poster boards**:

- **Topic 1. Preclinical models** = 9 Posters
- **Topic 2. Tumor Immunity and Microenvironment** = 23 Posters
- **Topic 3. Therapeutic modulation and monitoring of immune response** = 7 Posters
- **Topic 4. Combination therapy** = 7 Posters
- **Topic 5. Anti-cancer vaccines** = 2 Posters
- **Topic 6. Adoptive cell therapy** = 4 Posters

**TOTAL = 52 Posters**
ACKNOWLEDGMENTS

SPONSORS-EXHIBITORS-PARTNERS

For questions regarding sponsorship and exhibition, please contact Rose International.

Contact: Flora van Laer
E-mail: fvanlaer@rose-international.com
Telephone: +31 70 383 89 01

We thank all ITOC4 sponsors and partners.

The ITOC4 Organising Committee wishes to gratefully acknowledge our sponsors and exhibitors for supporting the 4th Immunotherapy of Cancer Conference (ITOC4).

SPONSORS

BRISTOL-MYERS SQUIBB
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.
View more on www.bms.com

INCYTE CORPORATION
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.
View more on www.incyte.com

LILLY ONCOLOGY
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.
To learn more about Lilly’s commitment to people with cancer, please visit www.lillyoncology.com

MILTENYI BIOTEC
Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our more than 25 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has more than 1,700 employees in 25 countries.
View more on www.miltenyibiotec.com

NANOSTRING
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.
View more on www.nanostring.com

THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
View more on www.thermofisher.com
MSD
For over a century, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com or www.msd.XX (for country-specific website).

EXHIBITORS

ACRIS ANTIBODIES
Acris Antibodies acquired by OriGene recently, offer > 1 million research products – everything you need for gene and protein based research: cDNA clones, siRNA, lysates, proteins, antibodies and many more. Acris Antibodies-OriGene EU is your “1 stop solution provider”. We support you as cancer research scientists in your gene as well as protein directed approaches.

Aquila BioMedical
Aquila BioMedical is an innovative, preclinical contract research organisation, offering clients world-leading research expertise in immuno-oncology, immunology and multiplex histology. We offer bespoke services, combining advanced models with protocolled techniques. The result? High-value data allowing you to define efficacy and mechanism of action of drug/antibody candidates. Partner with us to benefit from expert advice and data interpretation from superior and experienced scientists.

BioLegend

THE CANCER DRUG DEVELOPMENT FORUM (CDDF)
CDDF looks forward to welcoming you at the 4th edition of the Immunotherapy of Cancer Conference (ITOC4) in Prague. We will be available to meet you at the exhibition area, feel free to come and visit us at any time! The (CDDF) is an international organization providing a platform for all stakeholders involved in the development of oncology drugs. The aim of the not-for-profit organization is to accelerate the delivery of effective oncology agents to patients.

CROWN BIOSCIENCE
Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in Oncology and Metabolic Disease. Our unique collection of ready-to-run, well-validated in vitro, in vivo, ex vivo models, comprehensive Translational Platform, and immunotherapy models including syngeneic and humanized systems, enable clients to deliver superior clinical candidates.

DISCOVERX
DiscoverX Corporation is the leading supplier of innovative cell-based assays and services for drug discovery and development. The industry-leading portfolio of products and services, under the KINOMEscan®, PathHunter® and BioMAP® brands, enables rapid development of safe and effective biologic and small molecule drugs from early discovery through preclinical development.

IMMUDEX
Based in Copenhagen, Denmark, Immudex manufactures MHC Dextramers for the detection of antigen-specific T cells in life science research, in vitro diagnostics, and the development of immunotherapeutics and vaccines. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

www.msd.com or www.msd.XX (for country-specific website)

View more on www.acris-antibodies.com

View more on www.aquila-bm.com

View more on www.biolegend.com

View more on http://cddf.org or cddf_eu

View more on www.crownbio.com

View more on www.discoverx.com

View more on www.immudex.com
INCYTE CORPORATION
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.

MERCK-PFIZER ALLIANCE
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody.

MBL INTERNATIONAL
MBL International is a life science company focused on providing high quality, innovative, solutions-based products for life science research and clinical diagnostics. MBLI develops and manufactures a broad portfolio of monoclonal and polyclonal antibodies, MHC tetramers, fluorescent and recombinant proteins and ELISA kits for research related to allergy, apoptosis, autophagy, cancer, epigenetics, immunology, and neuroscience.

NANOSTRING
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.

PEPROTECH
PeproTech is a privately owned biotechnology company focusing on the development and manufacture of high quality cytokine products for the life-science and cell therapy market. With over 2,000 products PeproTech has developed and refined innovative protocols to ensure quality, reliability and consistency. We pride ourselves on being a trusted partner within the scientific community. Please contact: 020 7610 3062 or info@peprotech.co.uk

THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)
SITC is a 501(c)(3) non-profit professional society of over 1,600 influential scientists and practitioners from around the world who are dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through emphasis on high-caliber scientific meetings, education, and collaborations, SITC brings together all aspects of cancer immunology and immunotherapy.

THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.

THE CHINESE AMERICAN HEMATOLOGIST AND ONCOLOGIST NETWORK (CAHON)
For more information, please visit http://cahon.org

TUMORZENTRUM MÜNCHEN – TZM (MUNICH TUMOUR CENTRE)

PARTNERS
GENERAL INFORMATION

SECRETARIATS

SECRETARIAT
The Cancer Drug Development Forum (CDDF)
Avenue E. Mounier 83
1200 Brussels, Belgium
Phone: +32 (0) 2 775 02 15
Email: cddf@ecco-org.eu
Website: www.cddf.org

CONFERENCE MATTERS
Vienna Medical Academy
Contact: Catherine Tomek
E-mail: itoc@medacad.org
Telephone: +43 1 405 13 83 18

SPONSORSHIP AND EXHIBITION MATTERS
Exhibition Management & Congress Consultancy bv
Contact: Flora van Laer
E-mail: fvanlaer@rose-international.com
Telephone: +31 70 383 8901

CONFERENCE VENUE
Prague Congress Centre
Exhibition Area: Forum Hall Foyer, level 2
Adress: 5. kvetna 65 – CZ-14021 Prague, Czech Republic
Telephone: +420 261 171 111
www.kcp.cz

HOW TO REACH THE VENUE
The Prague Congress Centre is adjacent to the Vyšehrad station on Line C of the Prague underground railway network, providing convenient access by public transport from the city’s airport and all major rail and bus stations.

For further information on public transportation please see: www.kcp.cz/en/travel-to-pcc
REGISTRATION

Registration Hours
- Monday, March 20, 2017 09:00 - 18:30 hrs
- Tuesday, March 21, 2017 07:30 - 18:30 hrs
- Wednesday, March 22, 2017 08:00 - 13:30 hrs

Registration fees in Euro

<table>
<thead>
<tr>
<th>Payment received:</th>
<th>Early Bird until December 15, 2016</th>
<th>December 16 to March 10, 2017</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academia</td>
<td>450,-</td>
<td>550,-</td>
<td>650,-</td>
</tr>
<tr>
<td>Junior Participant(^1)</td>
<td>120,-</td>
<td>150,-</td>
<td>175,-</td>
</tr>
<tr>
<td>Industry</td>
<td>750,-</td>
<td>850,-</td>
<td>950,-</td>
</tr>
<tr>
<td>SITC Members – Academia(^2)</td>
<td>380,-</td>
<td>480,-</td>
<td>580,-</td>
</tr>
<tr>
<td>SITC Member – Junior Participant(^1,2)</td>
<td>100,-</td>
<td>130,-</td>
<td>155,-</td>
</tr>
<tr>
<td>Press/Media Pass Registration(^3)</td>
<td>Free of charge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome Reception for registered participants</td>
<td>No Fee, but registration is mandatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Dinner for registered participants</td>
<td></td>
<td>65,-</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration.

\(^2\) Please provide the SITC Promotional Code during on site registration. Note: the reduced registration fee only applies if the code is provided – make sure to inquire with SITC prior to your on site registration.

\(^3\) A Press ID confirming your status must be provided at the moment of your registration.

IMPORTANT:
Reduced registration fees are only applicable, if they have been credited to the congress account before the respective deadlines. Registering before a deadline without performing an actual payment was not sufficient to benefit from the reduction. Please note that a different fee applies for onsite payments and registrations. If the fee is not transferred to the congress bank account before the respective deadline expires the fee will be changed to the next applicable fee automatically.

What is covered by the registration fee?
- Admission to all scientific sessions
- Abstract book and programme
- Welcome reception (no fee but registration mandatory)
- Coffee breaks & Lunches
- Admission to exhibition

Cancellations
Please note that only written cancellations addressed to ITOC4 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:
- before January 31, 2017: 50 % refund
- after January 31, 2017: no refund

Replacements
Any replacement (i.e. change of delegate name) of a confirmed registration is subject to a 50 EUR charge per participant.
BADGES
For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

CATERING
Coffee breaks, lunches and a welcome reception have been scheduled. Exact times are listed in the programme overview.

CERTIFICATE OF ATTENDANCE
The 4th ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference. It is possible to claim a maximum of 12 CME points for attendance of scientific sessions at the ITOC4.

NETWORKING EVENTS

**Monday, March 20, 2017**
Welcome Cocktail in the exhibition area of the Prague Conference Center
*No fee for registered participants, but registration is mandatory!*

**Tuesday, March 21, 2017**
Conference dinner at the Sacré Coeur
Website: [www.sacrecoeur.cz](http://www.sacrecoeur.cz)
Contribution towards expenses: EUR 65,-
EXHIBITION
The exhibition is held in the Forum Hall Foyer 2 of the Conference Center. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

INSURANCE
By registering to the ITOC4 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

LANGUAGE & TRANSLATION
The official language of the conference is English. No simultaneous translation is provided.

LOST & FOUND
All enquiries should be directed to the registration desk in the entrance hall of Level 2. The organizers accept no responsibility for loss due to theft or negligence.

POLICIES
ITOC4 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC-4 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC representative observing the ITOC restrictions where appropriate.

Keynote Speaker
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
2017 Richard V. Smalley, MD Memorial Award and Lectureship Recipient
Cross-Disciplinary Insights and Emerging Tools of the Trade for Immuno-Oncology

Monday, 20 March 2017 | 14:00–15:00
Prague Congress Centre
Forum Hall
Prague, Czech Republic

Programme:

PD-L1—Friend or Foe? A Pathologist’s Perspective
Aleš Ryška, MD, PhD
Charles University Medical Faculty and University Hospital
Hradec Králové, Czech Republic

A Radiation Oncologist’s View of Immunotherapy
David Feltl, MD, PhD, MBA
General University Hospital
Prague, Czech Republic

The Role of Molecular Markers—A Medical Oncologist’s Perspective
Luboš Petruželka, MD, PhD
First Faculty of Medicine, Charles University and General University Hospital
Prague, Czech Republic

Panel discussion and audience Q&A to follow presentations

Bristol-Myers Squibb: Official Sponsor
4th Immunotherapy of Cancer Conference (ITOC4)

Bristol-Myers Squibb
SEE WHAT INNOVATIONS IN IMMUNO-ONCOLOGY COULD MEAN FOR YOUR PATIENTS

Our research and development team takes a broad and integrated approach in the development of new immunotherapies. This approach involves leveraging an existing portfolio of molecules that target and modulate the immune-suppressive environment that surrounds tumors. Deep expertise in antibody technology and chemistry helps us develop molecules that effectively modulate T-cell function. We’re also investigating novel approaches to redirect activated T cells to tumors.

To find out more about the immunotherapies we currently have in clinical development, please go to www.Lilly.com.